Jazz Pharmaceuticals Submits Supplemental NDA for Xywav in Idiopathic Hypersomnia
February 16th 2021, 6:52pm
ArticleBased on positive phase 3 results in adults with idiopathic hypersomnia, Jazz Pharmaceuticals submitted a supplemental new drug application (NDA) to the FDA for Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution.